データなし
データなし
Lucid Diagnostics Partners With VITALExam to Enhance Esophageal Precancer Detection for Firefighters
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard Esophageal DNA Test Accepted for Peer-Reviewed Publication
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday
Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital
Press Release: Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
このコンテンツを閲覧するにはログインが必要です。